The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Growth Is Projected For The Insomnia Therapeutics Market During The Forecast Period 2026–2030?
The insomnia therapeutics market has experienced robust expansion in recent years. It is projected to increase from $3.2 billion in 2025 to $3.38 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.7%. The growth observed in previous periods can be attributed to the rising prevalence of sleep disorders, increased stress and lifestyle-related insomnia, widespread use of prescription sleep aids, expanding retail pharmacy access, and a growing awareness of sleep health.
The insomnia therapeutics market is anticipated to show significant expansion over the next few years, with its size projected to reach $4.19 billion by 2030, achieving a compound annual growth rate (CAGR) of 5.5%. This projected growth can be attributed to several factors, including the expansion of digital sleep therapeutics, an increasing preference for non-pharmacological treatments, a rising aging population, the growing adoption of wearable sleep devices, and the broadening of telehealth-based insomnia management. Furthermore, major trends anticipated in the forecast period encompass the increasing embrace of cognitive behavioral therapy for insomnia, a surging demand for non-habit-forming sleep medications, the greater use of orexin receptor antagonists, the development of home-based sleep therapy solutions, and the enhanced integration of sleep tracking with overall treatment plans.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24255&type=smp
Which Major Factors Are Driving The Expansion Of The Insomnia Therapeutics Market?
Elevated stress levels and altered lifestyles are anticipated to propel the growth of the insomnia therapeutics market moving forward. These factors refer to psychological and behavioral shifts in daily routines and responsibilities that contribute to emotional strain and disrupted sleep patterns. The increase in stress levels and lifestyle changes is driven by constant digital connectivity, which erodes work-life boundaries and limits opportunities for true mental rest. Insomnia therapeutics serves a critical function by providing effective, science-backed treatment solutions that help reinstate healthy sleep patterns, alleviate sleep-related anxiety, and support mental well-being amidst current stressors. For example, in May 2024, the American Psychiatric Association (APA), a US-based organization of psychiatrists, reported that the percentage of U.S. adults feeling more anxious increased from 32% in 2022 to 37% in 2023, reaching 43% in 2024. Hence, the escalating stress levels and lifestyle changes are contributing significantly to the expansion of the insomnia therapeutics market.
What Market Segments Are Evaluated Within The Insomnia Therapeutics Market?
The insomnia therapeutics market covered in this report is segmented –
1) By Treatment Type: Drugs, Medical Devices
2) By Formulation: Tablets, Capsules, Liquid Solutions, Patches
3) By Route Of Administration: Oral, Intravenous, Transdermal, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Clinics, Wellness Centers
Subsegments:
1) By Drugs: Benzodiazepines, Nonbenzodiazepines, Antidepressants, Orexin Antagonists, Melatonin Antagonists, Other Drugs
2) By Medical Devices: Cognitive Behavioral Therapy Devices (CBT-I Devices), Polysomnography Devices, Sleep Tracking Devices, Neurostimulation Devices, Light Therapy Devices
What Industry Trends Are Redefining The Insomnia Therapeutics Market?
Leading companies in the insomnia therapeutics market are concentrating on developing advanced treatments, such as dual orexin receptor antagonists (DORAs), to offer targeted therapeutic choices with fewer side effects and enhanced safety profiles. A dual orexin receptor antagonist (DORA) is a type of medication that promotes sleep by inhibiting the wakefulness signaling pathway, achieved by blocking both orexin-1 and orexin-2 receptors in the brain, and is commonly used in insomnia treatment. For example, in June 2023, Idorsia Pharmaceuticals Ltd., a Switzerland-based pharmaceutical company, launched QUVIVIQ (daridorexant), which is a first-in-class dual orexin receptor antagonist (DORA) for addressing chronic insomnia disorder. This therapy is designed to decrease nighttime wakefulness without disturbing the natural sleep architecture, providing patients with improved sleep onset, better maintenance, and enhanced daytime functioning. Its approval represents a significant step forward in insomnia treatment, introducing a targeted mechanism of action that is distinct from traditional sedative-hypnotics and addressing the unmet need for long-term, non-habit-forming therapeutic solutions.
Who Are The Top Market Participants Influencing The Insomnia Therapeutics Market?
Major companies operating in the insomnia therapeutics market are Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck KGaA, Eisai Co. Ltd., Sumitomo Pharma Co. Ltd., Astellas Pharma Inc., Acadia Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Idorsia Ltd., Minerva Neurosciences, Neurim Pharmaceuticals Ltd., Big Health, Cerêve Inc., Innovative Neurological Devices, Neurovalens, Electromedical Products International Inc., Pear Therapeutics, ResMed Inc.
Read the full insomnia therapeutics market report here:
https://www.thebusinessresearchcompany.com/report/insomnia-therapeutics-global-market-report
Which Region Currently Holds The Largest Share Of The Insomnia Therapeutics Market?
North America was the largest region in the insomnia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the insomnia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Insomnia Therapeutics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24255&type=smp
Browse Through More Reports Similar to the Global Insomnia Therapeutics Market 2026, By The Business Research Company
Insomnia Market Report 2026
https://www.thebusinessresearchcompany.com/report/insomnia-global-market-report
Dental Sleep Medicine Market Report 2026
https://www.thebusinessresearchcompany.com/report/dental-sleep-medicine-global-market-report
Sleep Testing Services Market Report 2026
https://www.thebusinessresearchcompany.com/report/sleep-testing-services-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model